Upcoming Earnings: Q2 '26
Estimated EPS
-$0.11
Estimated Rev
$0.62M
$TSHA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 down -50.00% YoY • Taysha Gene Therapies expects its $276.6 million cash and cash equivalents as of March 31, 2026, to fund operations into 2028, but will require additional capital for R&D and commercialization.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.11 | -- | -- | N/A |
Q1 '26 | -$0.10 | -$0.12 | -24.14% | MISSED |
Q4 '25 | -$0.10 | -$0.08 | 16.32% | BEAT |
Q3 '25 | -$0.09 | -$0.09 | -1.01% | MISSED |
Q2 '25 | -$0.08 | -$0.09 | -15.57% | MISSED |